Nerandomilast
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Nerandomilast
- Molecular weight
- 448.98
- Structure (SMILES)
These details could not be displayed.
- bi 1015550
- BI 1015550
- BI 1015550 (C-14)
- BI 1015550 (Nerandomilast)
- BI 1015550 6 mg
- BI-1015550
- jascayd
- JASCAYD
- nerandomilast
- Nerandomilast
- nerandomilast [INN]
- NERANDOMILAST [USAN]
- Nerandomilast [WHO-DD]
- nerandomilast inn
- nerandomilast usan
- nerandomilast who dd
- ATC classification codes
- L04AA61
- CAS registry numbers
- 1423719-30-5
- ChEMBL ID
- CHEMBL5314532
- InChIKey
- UHYCLWAANUGUMN-UHFFFAOYSA-N
- RxNorm IDs (RxCUI)
- 2725523
- FDA ingredient codes (UNII)
- I5DGT51IB8
- 71278111
- 166177189
- Status
- Authorised
- Status date
- 15 Jul 2026
- Authorisation date
- 15 Jul 2026
- Approved indications
- Jascayd is indicated for the treatment of adult patients with Idiopathic Pulmonary Fibrosis (IPF). Jascayd is indicated for the treatment of adult patients with Progressive Pulmonary Fibrosis (PPF).
- Product number
- EMEA/H/C/006405
- Authorisation holder
- Boehringer Ingelheim International GmbH
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- Yes
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Idiopathic Pulmonary Fibrosis
European medicines record
- Patents
- 5
- Designations
- 5
- Earliest recorded loss of exclusivity
- 22 Oct 2038
- First in class
- No
- Fast track
- No
- Breakthrough designation
- Yes
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- example 2 [WO2013026797A1]
- Type
- Synthetic organic
- Drug name stem
- -ast
Mechanisms of action
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- phosphodiesterase 4B
- Gene symbol
- PDE4B
- Protein identifier
- Q07343
- Median affinity
- 8.14
- Affinity units
- pIC50
Investigated indications
- Condition
- Fibrosis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0006890
- Subject identifier
- D005355
- Condition identifier
- EFO_0000768
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004244
- Highest recorded phase
- 3
- Condition identifier
- EFO_0006890
- Condition identifier
- HP_0000083
- Highest recorded phase
- 1
- Condition identifier
- HP_0001399
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004976
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005100
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0015925
- Highest recorded phase
- 3
- Hydrogen bond acceptors
- 8
- Hydrogen bond donors
- 2
- Polar surface area
- 110.12
- Calculated partition coefficient (ALogP)
- 2.29
- Calculated partition coefficient (XLogP)
- 1.3
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 30
- Molecular formula
- C20H25ClN6O2S
- Monoisotopic mass
- 448.1448229
- Natural product
- No
- 0597-2465
- 0597-7313
Related records
Trials (36)
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- A Study in Healthy Chinese People to Test How Different Doses of BI 1015550 Are Taken up in the Body
- A Study in Healthy Men to Find Out How BI 1015550 is Taken up and Handled by the Body
- A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body
- A Study in Healthy Men to Test How Bosentan Influences the Amount of Nerandomilast in the Blood
- A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Midazolam in the Blood
- A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood
- A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Nerandomilast in the Blood
- A Study in Healthy People to Compare 2 Different Formulations of Nerandomilast Tablets When Taken With or Without Food
- A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the Body
- A Study in Healthy People to Compare How 2 Different Low Dose Formulations of BI 1015550 Are Taken up in the Body
- A Study in Healthy People to Test How BI 1015550 is Taken up in the Body When Given With or Without Food
- A Study in Healthy People to Test Whether Different Doses of BI 1015550 Have Potential to Induce Heart Rhythm Abnormalities
- A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
- A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
- A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Kidney Problems
- A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Liver Problems
- A Study to Test How Different Doses of Nerandomilast (BI 1015550) Are Taken up in the Body of Healthy Japanese Men
In development for (1)
- Interstitial lung disease Phase 3